Delving into the physics of cancer, with Lew Bender

Intra-tumourally injected therapeutics represent a novel approach to cancer cell death, with high tumour dispersion and cell penetration properties.

To discuss the potential of these therapeutics to kill tumours and elicit an adaptive immune response within mere days of injection, pharmaphorum spoke with Lew Bender, CEO of Intensity Therapeutics Inc.

Bender discusses the possibility of shifting the oncological treatment paradigm with intra-tumourally injected therapeutics, even for cancers that do not respond to immunotherapy, as well as how a business-trained mindset has led to outside-the-box – perhaps zigzagging – learnings.

You can listen to episode 222 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.